trending Market Intelligence /marketintelligence/en/news-insights/trending/D_zJB2Tvku7fYH1GUWSPsQ2 content esgSubNav
In This List

Editas Medicine director resigns

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Editas Medicine director resigns

Douglas Cole resigned as director of Editas Medicine Inc., effective Dec. 21.

Cole's decision to resign did not result from any disagreement with the company on any matter relating to the company's operations, policies or practices.